At present surgery remains the treatment of renal carcinoma of the principal means. Radiation therapy can be delayed appearance of local recurrence, but does not improve survival. Chemotherapy treatment is not ideal. The current rapid development of biological immune therapy, and achieved certain results.
1. Radical nephrectomy renal cell carcinoma should in principle be done first ligation of renal vessels to avoid the surgery due to tumor metastasis, and can reduce bleeding.
Should be removed under the following conditions: cases of metastatic renal cell carcinoma nephrectomy. confirmed cases of adrenal metastasis. the upper pole renal tumor and invaded the capsule, or a close adhesion by the adrenal. large upper pole renal tumor compression or displacement by the adrenal over.
Does the relative condition of lymph node dissection: small renal cell carcinoma and renal capsule without evidence of invasion, regional lymph node enlargement was not found. comprehensive treatment of palliative nephrectomy. Renal vein or inferior vena cava tumor thrombus in the operation should be taken to do.
2. Resection of renal cell carcinoma renal simple scope and radical surgery were similar, but not to lymph nodes. For palliative nephrectomy and renal small renal cell carcinoma, no local invasion and lymph node metastasis.
3. Nephron saving nephrectomy (NSN) are partial nephrectomy and tumor excavation technique for: solitary kidney renal cell carcinoma tumor; contralateral kidney of unilateral renal disease due to loss of function of some or incomplete nephrectomy; renal cell carcinoma, contralateral kidney has been in wide rows or required nephrectomy.
4. Embolization for unresectable renal cell carcinoma patients with advanced treatment. In addition to blocking the blood supply to tumor necrosis caused "Embolic nephrectomy", there is the role of immunization, useful ethanol embolization reported survival of more than 5 years. This technology can also serve as a huge preoperative renal support measures to help reduce the kidney surgery.
5. Use of laparoscopic resection of malignant tumors, is not completely removed to avoid the pain of the patient. With advances in medical technology may change the current situation.
6. Biological treatment: IL-2 (lL-2): the treatment of metastatic renal cell carcinoma has now become the standard preparation, can expand the number of T cells and stimulate the activation of T-cell growth, and enhance the patient's immune response. interferon : 1983 onwards for metastatic kidney cancer. Mild symptoms, small size of the tumor response is good. Interleukin -2 and interferon in patients with advanced renal cell carcinoma, response rate 20%. If more combined with 5-Fu, response rates can be increased to 40%. Most of the human body as interferon -2b receptor receptor, is recommended to use -2b interferon.
The difficulty in the treatment of renal cell carcinoma, its conventional chemotherapy or hormone therapy is not sensitive, unlike other cancers as effective. After treatment, patients are usually only an average of 10 months of survival.